(Total Views: 1304)
Posted On: 05/24/2017 10:15:25 PM
Post# of 15624
The DEA *must* reclassify cannabis from Schedule 1 to 3 (or) 4 once the FDA determines medical efficacy.
"GW Pharmaceuticals has initiated the process to get the drug approved by the FDA, but it is unclear if this will be successful or how long it could take."
http://www.newsweek.com/cannabis-marijuana-dr...ial-614982
I believe this is big news for the industry because we have a leader (GWPH) that is breaking the 'glass ceiling' wide open for OWCP and other medical cannabis researchers.
We all know what rescheduling cannabis in the United States would do to this stock and several others..
"GW Pharmaceuticals has initiated the process to get the drug approved by the FDA, but it is unclear if this will be successful or how long it could take."
http://www.newsweek.com/cannabis-marijuana-dr...ial-614982
I believe this is big news for the industry because we have a leader (GWPH) that is breaking the 'glass ceiling' wide open for OWCP and other medical cannabis researchers.
We all know what rescheduling cannabis in the United States would do to this stock and several others..
(0)
(0)
